{"id":"interferon-alfa-2b","rwe":[{"pmid":"41875235","year":"2026","title":"Ropeginterferon alfa-2b for pre-fibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction.","finding":"","journal":"Blood advances","studyType":"Clinical Study"},{"pmid":"41693220","year":"2026","title":"Intralesional Interferon Alfa-2b Versus Cryotherapy for Common Warts on the Hands and Feet: A Randomized, Open-Label, Controlled Trial.","finding":"","journal":"Journal of cosmetic dermatology","studyType":"Clinical Study"},{"pmid":"29999705","year":"2006","title":"Peginterferon Alfa.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"41634714","year":"2026","title":"Incidence and predictors of HBsAg loss following addition of pegylated interferon Alfa-2b in chronic hepatitis B patients suppressed by nucleos(t)ide analogues: a multicenter, prospective, cohort study.","finding":"","journal":"Virology journal","studyType":"Clinical Study"},{"pmid":"41505731","year":"2026","title":"Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance).","finding":"","journal":"Cancer immunology research","studyType":"Clinical Study"}],"tags":[{"label":"Interferon alpha","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"L03AB05","category":"atc"},{"label":"Subcutaneous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Chronic hepatitis C","category":"indication"},{"label":"Chronic type B viral hepatitis","category":"indication"},{"label":"Condyloma acuminatum","category":"indication"},{"label":"Follicular lymphoma","category":"indication"},{"label":"Hairy cell leukemia","category":"indication"},{"label":"Kaposi's sarcoma associated with AIDS","category":"indication"},{"label":"Schering","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antiviral Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":163.865,"date":"","count":106,"signal":"Influenza like illness","source":"DrugCentral FAERS","actionTaken":"Reported 106 times (LLR=164)"},{"llr":117.588,"date":"","count":152,"signal":"Product use in unapproved indication","source":"DrugCentral FAERS","actionTaken":"Reported 152 times (LLR=118)"},{"llr":75.401,"date":"","count":26,"signal":"Retinopathy","source":"DrugCentral FAERS","actionTaken":"Reported 26 times (LLR=75)"},{"llr":67.153,"date":"","count":58,"signal":"No adverse event","source":"DrugCentral FAERS","actionTaken":"Reported 58 times (LLR=67)"},{"llr":59.873,"date":"","count":104,"signal":"Depression","source":"DrugCentral FAERS","actionTaken":"Reported 104 times (LLR=60)"},{"llr":58.251,"date":"","count":16,"signal":"Retinal exudates","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=58)"},{"llr":54.296,"date":"","count":13,"signal":"Bladder cancer recurrent","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=54)"},{"llr":46.868,"date":"","count":247,"signal":"Fatigue","source":"DrugCentral FAERS","actionTaken":"Reported 247 times (LLR=47)"},{"llr":46.157,"date":"","count":35,"signal":"Osteonecrosis","source":"DrugCentral FAERS","actionTaken":"Reported 35 times (LLR=46)"},{"llr":44.767,"date":"","count":115,"signal":"Decreased appetite","source":"DrugCentral FAERS","actionTaken":"Reported 115 times (LLR=45)"},{"llr":43.039,"date":"","count":9,"signal":"Vogt-Koyanagi-Harada disease","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=43)"},{"llr":40.204,"date":"","count":20,"signal":"Retinal haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 20 times (LLR=40)"},{"llr":38.265,"date":"","count":10,"signal":"Exposure via body fluid","source":"DrugCentral FAERS","actionTaken":"Reported 10 times (LLR=38)"},{"llr":36.581,"date":"","count":20,"signal":"Hepatic cancer","source":"DrugCentral FAERS","actionTaken":"Reported 20 times (LLR=37)"},{"llr":35.003,"date":"","count":37,"signal":"Hypothyroidism","source":"DrugCentral FAERS","actionTaken":"Reported 37 times (LLR=35)"}],"commonSideEffects":[],"specialPopulations":{"Geriatric use":"In all clinical studies of INTRON A, including studies as monotherapy and in combination with REBETOL (ribavirin USP) Capsules, only small percentage of the subjects were aged 65 and over. These numbers were too few to determine if they respond differently from younger subjects except for the clinical trials of INTRON in combination with REBETOL, where elderly subjects had higher frequency of anemia (67%) than did younger patients (28%).","Paediatric use":"Safety and effectiveness in pediatric patients have not been established for indications other than chronic hepatitis and chronic hepatitis C. Safety and effectiveness in pediatric patients ranging in age from to 17 years have been established based upon one controlled clinical trial (see CLINICAL PHARMACOLOGY, INDICATIONS AND USAGE, and DOSAGE AND ADMINISTRATION, Chronic Hepatitis Pediatrics)."}},"trials":[],"aliases":[],"company":"Merck & Co.","patents":[{"type":"Biologic Exclusivity","filed":"June 04, 1986","source":"FDA Purple Book","status":"Active","expires":"November 21, 1995","territory":"US","patentNumber":"BLA 103132"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=INTERFERON ALFA-2B","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:08:53.946425+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:08:53.945985+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Interferon Alfa-2B","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:09:03.571047+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:09:01.228329+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=INTERFERON ALFA-2B","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:09:02.542218+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Interferon alpha/beta receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:09:03.570763+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201558/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:09:03.465320+00:00"}},"allNames":"intron a","offLabel":[],"synonyms":["interferon alfa-2b","intron A","interferon alfa-2b recombinant"],"timeline":[{"date":"1986-06-04","type":"positive","source":"DrugCentral","milestone":"FDA approval (Schering)"}],"approvals":[{"date":"1986-06-04","orphan":false,"company":"SCHERING","regulator":"FDA"}],"brandName":"Intron A","ecosystem":[{"indication":"Chronic hepatitis C","otherDrugs":[{"name":"boceprevir","slug":"boceprevir","company":"Merck Sharp Dohme"},{"name":"daclatasvir","slug":"daclatasvir","company":"Bristol Myers Squibb"},{"name":"dasabuvir","slug":"dasabuvir","company":"Abbvie Inc"},{"name":"elbasvir","slug":"elbasvir","company":"Merck Sharp Dohme"}],"globalPrevalence":58000000},{"indication":"Chronic type B viral hepatitis","otherDrugs":[{"name":"adefovir dipivoxil","slug":"adefovir-dipivoxil","company":"Gilead"},{"name":"entecavir","slug":"entecavir","company":"Bristol Myers Squibb"},{"name":"lamivudine","slug":"lamivudine","company":"Viiv Hlthcare"},{"name":"peginterferon alfa-2a","slug":"peginterferon-alfa-2a","company":"Hoffman-La Roche"}],"globalPrevalence":null},{"indication":"Condyloma acuminatum","otherDrugs":[{"name":"benzoin","slug":"benzoin","company":""},{"name":"cianidanol","slug":"cianidanol","company":""},{"name":"imiquimod","slug":"imiquimod","company":"Medicis"},{"name":"podophyllotoxin","slug":"podophyllotoxin","company":"Actavis Labs Ut Inc"}],"globalPrevalence":null},{"indication":"Follicular lymphoma","otherDrugs":[{"name":"copanlisib","slug":"copanlisib","company":"Bayer Healthcare Pharms"},{"name":"lenalidomide","slug":"lenalidomide","company":"Celgene"},{"name":"rituximab","slug":"rituximab","company":"Genentech"},{"name":"tazemetostat","slug":"tazemetostat","company":"Epizyme Inc"}],"globalPrevalence":120000},{"indication":"Hairy cell leukemia","otherDrugs":[{"name":"cladribine","slug":"cladribine","company":""},{"name":"moxetumomab pasudotox","slug":"moxetumomab-pasudotox","company":"Astrazeneca Ab"},{"name":"pentostatin","slug":"pentostatin","company":"Hospira Inc"}],"globalPrevalence":null},{"indication":"Kaposi's sarcoma associated with AIDS","otherDrugs":[{"name":"doxorubicin","slug":"doxorubicin","company":""}],"globalPrevalence":null},{"indication":"Malignant melanoma","otherDrugs":[{"name":"hydroxycarbamide","slug":"hydroxycarbamide","company":"Bristol Myers Squibb"},{"name":"talimogene laherparepvec","slug":"talimogene-laherparepvec","company":"Amgen"}],"globalPrevalence":330000}],"mechanism":{"novelty":"First-in-class","modality":"Small Molecule","drugClass":"Interferon alpha","explanation":"","oneSentence":"","technicalDetail":"Intron A binds to the interferon alpha receptor, activating the JAK-STAT signaling pathway, which leads to the transcription of genes involved in immune response and antiviral activity."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Interferon_alfa-2b","title":"Interferon alfa-2b","extract":"Interferon alfa-2b is an antiviral or antineoplastic drug. It is a recombinant form of the protein Interferon alpha-2 that was originally sequenced and produced recombinantly in E. coli in the laboratory of Charles Weissmann at the University of Zurich, in 1980. It was developed at Biogen, and ultimately marketed by Schering-Plough under the trade name Intron-A. It was also produced in 1986 in recombinant human form, in the Center for Genetic Engineering and Biotechnology of Havana, Cuba, under the name Heberon Alfa R."},"commercial":{"launchDate":"1986","_launchSource":"DrugCentral (FDA 1986-06-04, SCHERING)"},"purpleBook":{"bla":"103132","source":"FDA Purple Book","approvalDate":"June 04, 1986","licenseStatus":"Voluntarily Revoked","exclusivityExpiry":"November 21, 1995"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5205","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=INTERFERON%20ALFA-2B","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=INTERFERON ALFA-2B","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Interferon_alfa-2b","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://purplebooksearch.fda.gov/","fields":["biologicExclusivity"],"source":"FDA Purple Book"}],"_enrichedAt":"2026-03-30T12:06:10.038617","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:09:05.411610+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","company":"Merck Sharp & Dohme Corp.","brandName":"INTRON A","isOriginal":false,"marketingStatus":"BLA"}],"competitors":[{"drugName":"interferon beta-1a","drugSlug":"interferon-beta-1a","fdaApproval":"1996-05-17","relationship":"same-class"},{"drugName":"interferon beta-1b","drugSlug":"interferon-beta-1b","fdaApproval":"1993-07-23","relationship":"same-class"},{"drugName":"peginterferon alfa-2b","drugSlug":"peginterferon-alfa-2b","fdaApproval":"2001-01-19","relationship":"same-class"},{"drugName":"peginterferon alfa-2a","drugSlug":"peginterferon-alfa-2a","fdaApproval":"2002-10-16","relationship":"same-class"},{"drugName":"peginterferon beta-1a","drugSlug":"peginterferon-beta-1a","fdaApproval":"2014-08-15","relationship":"same-class"},{"drugName":"ropeginterferon alfa-2b","drugSlug":"ropeginterferon-alfa-2b","fdaApproval":"2021-11-12","relationship":"same-class"}],"genericName":"interferon alfa-2b","indications":{"approved":[{"name":"Chronic hepatitis C","source":"DrugCentral","snomedId":128302006,"regulator":"FDA","eligibility":{"age":"18 years and older","HCV antibody":"positive","prior treatment":"previously untreated with alpha interferon therapy or relapsed following alpha interferon therapy","compensated liver disease":{"WBC":"greater than or equal to 3000/mm3","albumin":"stable and within normal limits","history":"no history of hepatic encephalopathy, variceal bleeding, ascites, or other clinical signs of decompensation","bilirubin":"less than or equal to mg/dL","platelets":"greater than or equal to 70,000/mm3","prothrombin time":"less than seconds prolonged","serum creatinine":"normal or near normal"}},"usPrevalence":2400000,"globalPrevalence":58000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2024"},{"name":"Chronic type B viral hepatitis","source":"DrugCentral","snomedId":61977001,"regulator":"FDA","eligibility":{"age":"18 years and older","HCV antibody":"positive","prior treatment":"previously untreated with alpha interferon therapy or relapsed following alpha interferon therapy","compensated liver disease":{"WBC":"greater than or equal to 3000/mm3","albumin":"stable and within normal limits","history":"no history of hepatic encephalopathy, variceal bleeding, ascites, or other clinical signs of decompensation","bilirubin":"less than or equal to mg/dL","platelets":"greater than or equal to 70,000/mm3","prothrombin time":"less than seconds prolonged","serum creatinine":"normal or near normal"}}},{"name":"Condyloma acuminatum","source":"DrugCentral","snomedId":240542006,"regulator":"FDA","eligibility":{"age":"18 years and older","location":"external surfaces of the genital and perianal areas"}},{"name":"Follicular lymphoma","source":"DrugCentral","snomedId":55150002,"regulator":"FDA","eligibility":{"age":"18 years and older","stage":"clinically aggressive","prior treatment":"antracycline-containing combination chemotherapy"},"usPrevalence":null,"globalPrevalence":120000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"},{"name":"Hairy cell leukemia","source":"DrugCentral","snomedId":118613001,"regulator":"FDA","eligibility":{"age":"18 years and older"}},{"name":"Kaposi's sarcoma associated with AIDS","source":"DrugCentral","snomedId":420524008,"regulator":"FDA","eligibility":{"age":"18 years and older","immune system":"relatively intact (total CD4 count)"}},{"name":"Malignant melanoma","source":"DrugCentral","snomedId":372244006,"regulator":"FDA","eligibility":{"age":"18 years and older","stage":"high risk for systemic recurrence","time since surgery":"within 56 days"},"usPrevalence":100000,"globalPrevalence":330000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"interferon-beta-1a","brandName":"interferon beta-1a","genericName":"interferon beta-1a","approvalYear":"1996","relationship":"same-class"},{"drugId":"interferon-beta-1b","brandName":"interferon beta-1b","genericName":"interferon beta-1b","approvalYear":"1993","relationship":"same-class"},{"drugId":"peginterferon-alfa-2b","brandName":"peginterferon alfa-2b","genericName":"peginterferon alfa-2b","approvalYear":"2001","relationship":"same-class"},{"drugId":"peginterferon-alfa-2a","brandName":"peginterferon alfa-2a","genericName":"peginterferon alfa-2a","approvalYear":"2002","relationship":"same-class"},{"drugId":"peginterferon-beta-1a","brandName":"peginterferon beta-1a","genericName":"peginterferon beta-1a","approvalYear":"2014","relationship":"same-class"},{"drugId":"ropeginterferon-alfa-2b","brandName":"ropeginterferon alfa-2b","genericName":"ropeginterferon alfa-2b","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02506153","phase":"PHASE3","title":"Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-10","conditions":["Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Metastatic Cutaneous Melanoma","Metastatic Mucosal Melanoma","Metastatic Non-Cutaneous Melanoma","Non-Cutaneous Melanoma","Recurrent Cutaneous Melanoma","Recurrent Mucosal Melanoma","Recurrent Non-Cutaneous Melanoma"],"enrollment":1301,"completionDate":"2027-01-23"},{"nctId":"NCT00569127","phase":"PHASE3","title":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-12-01","conditions":["Colorectal Neuroendocrine Tumor G1","Gastric Neuroendocrine Tumor G1","Neuroendocrine Neoplasm","Neuroendocrine Tumor","Neuroendocrine Tumor G2"],"enrollment":427,"completionDate":"2027-01-31"},{"nctId":"NCT06510374","phase":"PHASE3","title":"Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ferring Pharmaceuticals","startDate":"2024-10-01","conditions":["Intermediate Risk Non-Muscle Invasive Bladder Cancer"],"enrollment":454,"completionDate":"2031-06-30"},{"nctId":"NCT06079879","phase":"PHASE3","title":"A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":["Essential Thrombocythemia"],"enrollment":340,"completionDate":"2028-08-18"},{"nctId":"NCT07468916","phase":"PHASE2","title":"Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2026-03-29","conditions":["Atypical Chronic Myeloid Leukemia","Chronic Myelomonocytic Leukemia","Myelodysplastic/Myeloproliferative Neoplasm","Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified","Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified"],"enrollment":35,"completionDate":"2032-03-30"},{"nctId":"NCT02737046","phase":"PHASE2","title":"Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2016-12-12","conditions":["Adult T-cell Leukemia-Lymphoma","ATLL"],"enrollment":15,"completionDate":"2025-12-31"},{"nctId":"NCT04380545","phase":"PHASE1,PHASE2","title":"Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-13","conditions":["Stage III Hepatocellular Carcinoma AJCC v8","Stage IIIA Hepatocellular Carcinoma AJCC v8","Stage IIIB Hepatocellular Carcinoma AJCC v8","Stage IV Hepatocellular Carcinoma AJCC v8","Stage IVA Hepatocellular Carcinoma AJCC v8","Stage IVB Hepatocellular Carcinoma AJCC v8","Unresectable Fibrolamellar Carcinoma"],"enrollment":15,"completionDate":"2028-02-28"},{"nctId":"NCT06545955","phase":"PHASE3","title":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ferring Pharmaceuticals","startDate":"2024-10-01","conditions":["Non-muscle Invasive Bladder Cancer With Carcinoma in Situ"],"enrollment":250,"completionDate":"2030-12-31"},{"nctId":"NCT07445893","phase":"NA","title":"A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV","status":"NOT_YET_RECRUITING","sponsor":"Duan Minghui","startDate":"2026-02-24","conditions":["Polycythemia Vera (PV)"],"enrollment":30,"completionDate":"2028-12-30"},{"nctId":"NCT00003641","phase":"PHASE3","title":"High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"1999-03-25","conditions":["Melanoma (Skin)"],"enrollment":1150,"completionDate":"2026-12"},{"nctId":"NCT04093323","phase":"PHASE2","title":"Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2024-11-13","conditions":["HLA-A2 Positive Cells Present","Refractory Melanoma"],"enrollment":1,"completionDate":"2025-06-19"},{"nctId":"NCT01274338","phase":"PHASE3","title":"Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-05-25","conditions":["Melanoma of Unknown Primary","Recurrent Melanoma","Stage IIIB Cutaneous Melanoma AJCC v7","Stage IIIC Cutaneous Melanoma AJCC v7","Stage IV Cutaneous Melanoma AJCC v6 and v7"],"enrollment":1673,"completionDate":"2026-03-19"},{"nctId":"NCT05676827","phase":"","title":"Pain, Central Sensitization and Psychoemotional State in Patients With Chronic Masticatory Muscle Pain","status":"ENROLLING_BY_INVITATION","sponsor":"Wroclaw Medical University","startDate":"2023-09-01","conditions":["TMD","Masticatory Muscle Pain"],"enrollment":102,"completionDate":"2026-12"},{"nctId":"NCT04379518","phase":"PHASE1,PHASE2","title":"Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2020-11-17","conditions":["Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm","Symptomatic COVID-19 Infection Laboratory-Confirmed"],"enrollment":4,"completionDate":"2023-03-15"},{"nctId":"NCT02948426","phase":"PHASE1","title":"Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-02-08","conditions":["Fallopian Tube Cancer","Ovarian Cancer","Primary Peritoneal Cancer"],"enrollment":18,"completionDate":"2020-09-29"},{"nctId":"NCT00780910","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-11","conditions":["Chronic Hepatitis C"],"enrollment":109,"completionDate":"2010-10"},{"nctId":"NCT00781274","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-12","conditions":["Hepatitis C"],"enrollment":32,"completionDate":"2010-07"},{"nctId":"NCT00539591","phase":"PHASE2","title":"Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2008-05-09","conditions":["Malignant Melanoma"],"enrollment":29,"completionDate":"2026-05"},{"nctId":"NCT01708941","phase":"PHASE2","title":"Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-01-18","conditions":["Recurrent Melanoma","Stage IIIA Cutaneous Melanoma AJCC v7","Stage IIIB Cutaneous Melanoma AJCC v7","Stage IIIC Cutaneous Melanoma AJCC v7","Stage IV Cutaneous Melanoma AJCC v6 and v7"],"enrollment":88,"completionDate":"2026-03-19"},{"nctId":"NCT07231276","phase":"PHASE4","title":"Prospective Cohort Study on PEG-IFN-α-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2026-01-01","conditions":["HBV","Chronic Hepatitis B Virus"],"enrollment":113,"completionDate":"2028-10-01"},{"nctId":"NCT07223632","phase":"PHASE1,PHASE2","title":"Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanda Pharmaceuticals","startDate":"2025-05-13","conditions":["Charcot Marie Tooth Disease (CMT)","Neuromuscular Diseases (NMD)"],"enrollment":1,"completionDate":"2026-03"},{"nctId":"NCT02370329","phase":"PHASE2","title":"P1101 in Treating Patients With Myelofibrosis","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-08-12","conditions":["Primary Myelofibrosis","Secondary Myelofibrosis"],"enrollment":11,"completionDate":"2023-11-30"},{"nctId":"NCT07199413","phase":"PHASE1","title":"Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-03-01","conditions":["Brain Metastases","Leptomeningeal Metastasis"],"enrollment":20,"completionDate":"2029-04-01"},{"nctId":"NCT05100823","phase":"NA","title":"Validation of Therapeutic Efficacy Targeting the Splicing Variants in Cystic Fibrosis and CFTR Pathologies","status":"TERMINATED","sponsor":"University Hospital, Montpellier","startDate":"2022-03-30","conditions":["Cystic Fibrosis","CFTR Gene Mutation"],"enrollment":16,"completionDate":"2025-02-17"},{"nctId":"NCT04182100","phase":"PHASE2","title":"Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply","status":"COMPLETED","sponsor":"PharmaEssentia Japan K.K.","startDate":"2019-12-20","conditions":["Polycythemia Vera (PV)"],"enrollment":29,"completionDate":"2021-03-08"},{"nctId":"NCT03911531","phase":"","title":"Whole Exome Sequencing and Whole Genome Sequencing for Nonimmune Fetal/Neonatal Hydrops","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2019-01-15","conditions":["Nonimmune Fetal Hydrops","Nonimmune Hydrops in Neonate","Genetic Disorders"],"enrollment":55,"completionDate":"2028-12-31"},{"nctId":"NCT03899987","phase":"PHASE2","title":"Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2019-11-29","conditions":["Prostate Adenocarcinoma","Stage I Prostate Cancer AJCC v8","Stage II Prostate Cancer AJCC v8","Stage IIA Prostate Cancer AJCC v8","Stage IIB Prostate Cancer AJCC v8","Stage IIC Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8","Stage IIIA Prostate Cancer AJCC v8","Stage IIIB Prostate Cancer AJCC v8","Stage IIIC Prostate Cancer AJCC v8"],"enrollment":12,"completionDate":"2026-11-29"},{"nctId":"NCT07071636","phase":"PHASE4","title":"Clinical Efficacy of Pegylated Interferon Alpha-2b Combined With Nucleos(t)Ide Analogues in the Treatment of Chronic Hepatitis B Patients","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-08-15","conditions":["Metabolic Dysfunction-Associated Steatotic Liver Disease","Chronic Hepatitis B"],"enrollment":830,"completionDate":"2029-09-30"},{"nctId":"NCT07051213","phase":"NA","title":"The Belgian Genome Resource to Resolve Rare Diseases","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2021-06-02","conditions":["Intellectual Developmental Disorder","Malformations","Dysmorphia","Developmental Delay (Disorder)"],"enrollment":567,"completionDate":"2025-01-31"},{"nctId":"NCT04638439","phase":"PHASE1","title":"The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2022-08-17","conditions":["Chronic Hepatitis B Infection","Chronic Hepatitis D Infection"],"enrollment":20,"completionDate":"2025-05-14"},{"nctId":"NCT05756166","phase":"PHASE1,PHASE2","title":"Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2024-02-16","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Triple-Negative Breast Carcinoma","Unresectable Triple-Negative Breast Carcinoma"],"enrollment":5,"completionDate":"2025-06-19"},{"nctId":"NCT07025122","phase":"","title":"Fatigue in Multiple Sclerosis and Its Relationship to Inflammatory and Neurodegenerative Markers of the Disease","status":"ENROLLING_BY_INVITATION","sponsor":"University Hospital, Martin","startDate":"2024-01-26","conditions":["Fatigue in Multiple Sclerosis","Multiple Sclerosis","Neurofilaments Light Chains","GFAP","HLA DRB 1501","BCL6 (rs969625)","OS9 (rs701006)"],"enrollment":100,"completionDate":"2028-12-31"},{"nctId":"NCT03710876","phase":"PHASE3","title":"Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ferring Ventures Limited","startDate":"2019-01-21","conditions":["Malignant Pleural Mesothelioma"],"enrollment":53,"completionDate":"2026-04"},{"nctId":"NCT04418219","phase":"PHASE1,PHASE2","title":"Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Thomas Jefferson University","startDate":"2020-12-21","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma","Prognostic Stage IV Breast Cancer AJCC v8","Recurrent Breast Carcinoma","Refractory Breast Carcinoma"],"enrollment":0,"completionDate":"2024-01-01"},{"nctId":"NCT06137950","phase":"PHASE1","title":"Interferon Alpha Therapy for Cervical CINI and HPV Infection","status":"COMPLETED","sponsor":"Mongolian National University of Medical Sciences","startDate":"2023-11-07","conditions":["Cervical Dysplasia","HPV Infection"],"enrollment":60,"completionDate":"2025-03-31"},{"nctId":"NCT06900166","phase":"PHASE4","title":"Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg","status":"NOT_YET_RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-04-01","conditions":["Chronic Hepatitis B"],"enrollment":360,"completionDate":"2029-04"},{"nctId":"NCT02869074","phase":"","title":"Molecular and Clinical Profile of Von Willebrand Disease in Spain","status":"COMPLETED","sponsor":"Spanish Society of Thrombosis and Haemostasis","startDate":"2017-10-03","conditions":["Von Willebrand Disease"],"enrollment":790,"completionDate":"2021-09-25"},{"nctId":"NCT01986712","phase":"","title":"A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma","status":"COMPLETED","sponsor":"St. Luke's Hospital and Health Network, Pennsylvania","startDate":"2013-12","conditions":["Melanoma"],"enrollment":50,"completionDate":"2019-09-17"},{"nctId":"NCT06802718","phase":"PHASE3","title":"Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2023-01-01","conditions":["Acute Myeloid Leukemia"],"enrollment":96,"completionDate":"2026-12"},{"nctId":"NCT06777173","phase":"NA","title":"Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for CHB in Adults","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Ditan Hospital","startDate":"2023-12-01","conditions":["Chronic Hepatitis b","Immunotherapy"],"enrollment":180,"completionDate":"2026-11-01"},{"nctId":"NCT06734663","phase":"NA","title":"Clinical Outcomes of Sutured Versus Sutureless Conjunctival Autograft in Primary Pterygium Excision","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-12-15","conditions":["Pterygium of Conjunctiva and Cornea","Pterygium of Both Eyes","Pterygium"],"enrollment":70,"completionDate":"2025-09-01"},{"nctId":"NCT04116502","phase":"PHASE3","title":"MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2019-10-25","conditions":["Polycythemia Vera"],"enrollment":586,"completionDate":"2030-04-01"},{"nctId":"NCT06002490","phase":"PHASE3","title":"A Study to Evaluate P1101 in Japanese PV Patients","status":"COMPLETED","sponsor":"PharmaEssentia Japan K.K.","startDate":"2023-10-17","conditions":["Polycythemia Vera (PV)"],"enrollment":21,"completionDate":"2024-07-26"},{"nctId":"NCT06111950","phase":"NA","title":"Study of the Pathophysiology of RNU4ATAC and RTTN Associated Syndromes","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-08-27","conditions":["Taybi Linder Syndrome","Microcephalic Osteodysplastic Primordial Dwarfism Types I and III","Roifman Syndrome","Lowry Wood Syndrome"],"enrollment":45,"completionDate":"2029-08-27"},{"nctId":"NCT03003325","phase":"PHASE2","title":"The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV","status":"COMPLETED","sponsor":"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS","startDate":"2017-02-02","conditions":["Polycythemia Vera"],"enrollment":127,"completionDate":"2023-03-31"},{"nctId":"NCT02001818","phase":"PHASE2","title":"Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia","status":"COMPLETED","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2014-04-11","conditions":["Chronic Myeloid Leukaemia"],"enrollment":60,"completionDate":"2022-01-07"},{"nctId":"NCT04226950","phase":"PHASE2","title":"Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2020-01-10","conditions":["Essential Thrombocytopenia"],"enrollment":40,"completionDate":"2024-11-20"},{"nctId":"NCT05395507","phase":"PHASE2","title":"Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-06-01","conditions":["Essential Thrombocytopenia"],"enrollment":194,"completionDate":"2025-06-30"},{"nctId":"NCT01340573","phase":"","title":"Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03-23","conditions":["Chronic Hepatitis C"],"enrollment":3,"completionDate":"2007-10-29"},{"nctId":"NCT06450145","phase":"NA","title":"Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant APL","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2024-05-01","conditions":["Tumour"],"enrollment":15,"completionDate":"2025-12-31"},{"nctId":"NCT01353911","phase":"PHASE2","title":"Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-27","conditions":["Hepatitis C, Chronic"],"enrollment":368,"completionDate":"2015-03-10"},{"nctId":"NCT01440595","phase":"PHASE2","title":"Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-28","conditions":["Hepatitis C, Chronic"],"enrollment":5,"completionDate":"2012-05-01"},{"nctId":"NCT05770466","phase":"PHASE3","title":"Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2022-04-01","conditions":["COVID-19"],"enrollment":134,"completionDate":"2023-01-11"},{"nctId":"NCT04846491","phase":"PHASE3","title":"A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2019-12-04","conditions":["Chronic Hepatitis B"],"enrollment":475,"completionDate":"2023-12-07"},{"nctId":"NCT06196632","phase":"","title":"Development and Validation of Models to Predict Functional Cure in Patients With CHB After Peg-IFN Based Therapy","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-01-06","conditions":["Hepatitis B, Chronic"],"enrollment":1000,"completionDate":"2025-12-31"},{"nctId":"NCT04703595","phase":"","title":"Chronic Cough and CANVAS (Cerebellar Ataxia With Neuropathy and Bilateral Vestibular Areflexia Syndrome)","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2022-01-01","conditions":["Cough","Cerebellar Ataxia","Gastroesophageal Reflux"],"enrollment":50,"completionDate":"2023-09-30"},{"nctId":"NCT01545141","phase":"PHASE1,PHASE2","title":"Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2012-10","conditions":["Colorectal Cancer","Colorectal Carcinoma","Colorectal Tumors","Neoplasms, Colorectal"],"enrollment":15,"completionDate":"2017-04-08"},{"nctId":"NCT00574730","phase":"NA","title":"CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2001-05-23","conditions":["Non-Hodgkins Lymphoma"],"enrollment":27,"completionDate":"2012-06-07"},{"nctId":"NCT04081389","phase":"PHASE1","title":"Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-12-06","conditions":["Anatomic Stage 0 Breast Cancer AJCC v8","Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Early-Stage Breast Carcinoma","Estrogen Receptor Negative","HER2/Neu Negative","Progesterone Receptor Negative","Prognostic Stage 0 Breast Cancer AJCC v8","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Triple-Negative Breast Carcinoma"],"enrollment":9,"completionDate":"2023-02-27"},{"nctId":"NCT06020456","phase":"","title":"Genetic Factors of the Desmopressin Response in Carriers of Hemophilia A","status":"COMPLETED","sponsor":"Groupe Maladies hémorragiques de Bretagne","startDate":"2022-01-01","conditions":["Carrier of Hemophilia A","Desmopressin","Factor VIII Deficiency"],"enrollment":361,"completionDate":"2023-04-01"},{"nctId":"NCT00846430","phase":"PHASE2","title":"Medical Treatment of \"High-Risk\" Neurofibromas","status":"COMPLETED","sponsor":"Corewell Health West","startDate":"2008-10","conditions":["Neurofibromatosis 1"],"enrollment":9,"completionDate":"2017-05"},{"nctId":"NCT01180790","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2010-09","conditions":["Hepatitis C"],"enrollment":122,"completionDate":"2013-04"},{"nctId":"NCT05988879","phase":"","title":"Functional Cure of Hepatitis B in HIV/HBV Co-infected Patients","status":"RECRUITING","sponsor":"Guangzhou 8th People's Hospital","startDate":"2023-08-02","conditions":["AIDS","Hepatitis B"],"enrollment":60,"completionDate":"2028-08-02"},{"nctId":"NCT03599453","phase":"EARLY_PHASE1","title":"Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-01-09","conditions":["Triple -Negative Breast Cancer","Estrogen Receptor Negative","HER2/Neu Negative","Anatomic Stage IV Breast Cancer AJCC","Progesterone Receptor Negative"],"enrollment":8,"completionDate":"2023-03-21"},{"nctId":"NCT00062010","phase":"PHASE2","title":"Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2004-05-26","conditions":["Lung Cancer"],"enrollment":37,"completionDate":"2012-08"},{"nctId":"NCT01935089","phase":"PHASE2","title":"Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV","status":"COMPLETED","sponsor":"The Wistar Institute","startDate":"2013-08-07","conditions":["HIV-1 Infection"],"enrollment":20,"completionDate":"2016-05-02"},{"nctId":"NCT00049530","phase":"PHASE2","title":"PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2004-01-13","conditions":["Melanoma (Skin)"],"enrollment":32,"completionDate":"2014-06"},{"nctId":"NCT05922306","phase":"EARLY_PHASE1","title":"Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B","status":"RECRUITING","sponsor":"Anhui Medical University","startDate":"2023-07","conditions":["Hepatitis B, Chronic"],"enrollment":1084,"completionDate":"2027-12"},{"nctId":"NCT00003444","phase":"PHASE3","title":"Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-03-29","conditions":["Melanoma (Skin)"],"enrollment":167,"completionDate":""},{"nctId":"NCT00134030","phase":"PHASE3","title":"Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-11-14","conditions":["Localized Osteosarcoma","Metastatic Osteosarcoma"],"enrollment":1334,"completionDate":"2022-09-30"},{"nctId":"NCT03771677","phase":"NA","title":"To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-12-01","conditions":["Hepatitis B"],"enrollment":400,"completionDate":"2024-12-30"},{"nctId":"NCT01359956","phase":"PHASE3","title":"Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma","status":"COMPLETED","sponsor":"National Cancer Institute, Naples","startDate":"2002-04","conditions":["Malignant Melanoma","Recurrent Melanoma"],"enrollment":269,"completionDate":"2011-02"},{"nctId":"NCT05806918","phase":"PHASE3","title":"Non-inferiority Study of ZK-A03 in Treatment of Herpes Zoster Before and After the Alteration of the Active Ingredient Manufacturer","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2023-04-01","conditions":["Herpes Zoster"],"enrollment":368,"completionDate":"2023-08-30"},{"nctId":"NCT03117816","phase":"PHASE3","title":"ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission","status":"COMPLETED","sponsor":"Philipps University Marburg","startDate":"2017-05-04","conditions":["Chronic Myeloid Leukemia in Remission"],"enrollment":214,"completionDate":"2022-12-12"},{"nctId":"NCT02634294","phase":"PHASE2,PHASE3","title":"Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2015-08","conditions":["Hematological Neoplasms","Recurrence"],"enrollment":30,"completionDate":"2021-12"},{"nctId":"NCT00573378","phase":"PHASE2","title":"Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2007-09","conditions":["Chronic Myeloid Leukemia"],"enrollment":12,"completionDate":"2015-12"},{"nctId":"NCT03872479","phase":"PHASE1,PHASE2","title":"Single Ascending Dose Study in Participants With LCA10","status":"UNKNOWN","sponsor":"Editas Medicine, Inc.","startDate":"2019-09-26","conditions":["Leber Congenital Amaurosis 10","Inherited Retinal Dystrophies","Eye Diseases, Hereditary","Retinal Disease","Retinal Degeneration","Vision Disorders","Eye Disorders Congenital"],"enrollment":34,"completionDate":"2025-05-23"},{"nctId":"NCT00679289","phase":"PHASE2","title":"Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2008-03-28","conditions":["Metastatic Melanoma","Cutaneous Melanoma"],"enrollment":36,"completionDate":"2014-02-03"},{"nctId":"NCT02218164","phase":"PHASE2","title":"Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2014-08-12","conditions":["Squamous Cell Carcinoma of Skin","Carcinoma, Squamous Cell"],"enrollment":8,"completionDate":"2018-06-25"},{"nctId":"NCT02089685","phase":"PHASE1,PHASE2","title":"Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-17","conditions":["Renal Cell Carcinoma","Melanoma"],"enrollment":295,"completionDate":"2021-04-01"},{"nctId":"NCT04774107","phase":"PHASE1","title":"The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2020-11-26","conditions":["Hepatitis C, Chronic"],"enrollment":17,"completionDate":"2022-07-18"},{"nctId":"NCT01678131","phase":"PHASE1","title":"Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-30","conditions":["Chronic Hepatitis C"],"enrollment":31,"completionDate":"2013-09-02"},{"nctId":"NCT04988217","phase":"PHASE1,PHASE2","title":"Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2021-09-15","conditions":["Coronavirus Disease 2019"],"enrollment":173,"completionDate":"2022-07-28"},{"nctId":"NCT05466565","phase":"","title":"Antiviral Therapy for Patients With Liver Cancer After Surgery","status":"RECRUITING","sponsor":"Xiangya Hospital of Central South University","startDate":"2021-12-01","conditions":["Hepatocellular Carcinoma"],"enrollment":360,"completionDate":"2027-12-31"},{"nctId":"NCT04669015","phase":"PHASE3","title":"Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19","status":"UNKNOWN","sponsor":"Genova Inc.","startDate":"2021-06-10","conditions":["Covid19"],"enrollment":914,"completionDate":"2022-08"},{"nctId":"NCT04658251","phase":"","title":"Study of New Mutations in Cone Disorders","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2021-03-03","conditions":["Retinal Dystrophy, Cone-Rod","Cone Dystrophy","Cone Rod Dystrophy","Macular Degeneration"],"enrollment":20,"completionDate":"2026-03"},{"nctId":"NCT01387763","phase":"PHASE3","title":"A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms","status":"COMPLETED","sponsor":"Thomas Stauffer Larsen","startDate":"2012-01","conditions":["Polycythemia Vera","Essential Thrombocythemia","Primary Myelofibrosis"],"enrollment":202,"completionDate":"2020-06"},{"nctId":"NCT04943679","phase":"","title":"Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-06-15","conditions":["Hepatocellular Carcinoma"],"enrollment":15,"completionDate":"2024-12-31"},{"nctId":"NCT00003656","phase":"PHASE2","title":"Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"1999-01","conditions":["Kidney Cancer"],"enrollment":26,"completionDate":"2008-05"},{"nctId":"NCT05172037","phase":"PHASE3","title":"Novaferon in Non-hospitalized Adult Patients With Mild COVID-19","status":"UNKNOWN","sponsor":"Genova Inc.","startDate":"2021-10-28","conditions":["Covid19"],"enrollment":222,"completionDate":"2022-06"},{"nctId":"NCT03403634","phase":"PHASE2","title":"Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2018-04-19","conditions":["Metastatic Carcinoma in the Liver","Recurrent Colorectal Carcinoma","Stage IV Colorectal Cancer AJCC v7","Stage IVA Colorectal Cancer AJCC v7","Stage IVB Colorectal Cancer AJCC v7"],"enrollment":19,"completionDate":"2021-08-29"},{"nctId":"NCT02982720","phase":"PHASE2","title":"Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron","status":"TERMINATED","sponsor":"Aiwu Ruth He, MD","startDate":"2017-07-05","conditions":["Advanced Cholangiocarcinoma"],"enrollment":4,"completionDate":"2018-02-09"},{"nctId":"NCT04708158","phase":"PHASE3","title":"Novaferon for COVID-19 Treatment Trial (NCTT-005)","status":"UNKNOWN","sponsor":"Genova Inc.","startDate":"2021-03-25","conditions":["Covid19"],"enrollment":385,"completionDate":"2023-04-30"},{"nctId":"NCT02343224","phase":"PHASE2","title":"Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas","status":"COMPLETED","sponsor":"Emory University","startDate":"2014-11","conditions":["Juvenile Pilocytic Astrocytomas","Optic Pathway Gliomas"],"enrollment":9,"completionDate":"2020-11-11"},{"nctId":"NCT04382937","phase":"PHASE3","title":"Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2016-01-12","conditions":["Chronic Hepatitis C Virus Infection"],"enrollment":222,"completionDate":"2020-07-15"},{"nctId":"NCT02323659","phase":"PHASE4","title":"Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas","status":"TERMINATED","sponsor":"Polish Lymphoma Research Group","startDate":"2014-06-01","conditions":["Lymphoma, T-Cell, Cutaneous","Mycosis Fungoides"],"enrollment":100,"completionDate":"2018-03-31"},{"nctId":"NCT01482767","phase":"PHASE3","title":"Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-04","conditions":["HIV Infections","Hepatitis C"],"enrollment":262,"completionDate":"2015-04"},{"nctId":"NCT00000694","phase":"PHASE1","title":"A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["Sarcoma, Kaposi","HIV Infections"],"enrollment":18,"completionDate":"1992-08"},{"nctId":"NCT00006325","phase":"PHASE1","title":"Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":54,"completionDate":"2004-03"},{"nctId":"NCT00001114","phase":"PHASE2","title":"The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["Sarcoma, Kaposi","HIV Infections"],"enrollment":90,"completionDate":"2000-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Subcutaneous","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"INTRON A"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"2420","NDDF":"003424","UNII":"43K1W2T1M6","VANDF":"4018794","RXNORM":"545290","UMLSCUI":"C0002199","chemblId":"CHEMBL1201558","ChEMBL_ID":"CHEMBL1201558","KEGG_DRUG":"D02745","DRUGBANK_ID":"DB00105","PUBCHEM_CID":"71306834","SNOMEDCT_US":"108797002","MESH_DESCRIPTOR_UI":"D000077190"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1986-","companyName":"Schering","relationship":"Original Developer"}],"publicationCount":970,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L03AB05","allCodes":["L03AB05"]},"biosimilarFilings":[],"originalDeveloper":"Schering","recentPublications":[{"date":"2026 Mar 24","pmid":"41875235","title":"Ropeginterferon alfa-2b for pre-fibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction.","journal":"Blood advances"},{"date":"2026 Feb","pmid":"41693220","title":"Intralesional Interferon Alfa-2b Versus Cryotherapy for Common Warts on the Hands and Feet: A Randomized, Open-Label, Controlled Trial.","journal":"Journal of cosmetic dermatology"},{"date":"2006","pmid":"29999705","title":"Peginterferon Alfa.","journal":""},{"date":"2026 Feb 3","pmid":"41634714","title":"Incidence and predictors of HBsAg loss following addition of pegylated interferon Alfa-2b in chronic hepatitis B patients suppressed by nucleos(t)ide analogues: a multicenter, prospective, cohort study.","journal":"Virology journal"},{"date":"2026 Mar 4","pmid":"41505731","title":"Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance).","journal":"Cancer immunology research"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Merck & Co.","companyId":"merck","modality":"Recombinant protein","firstApprovalDate":"1986","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1986-06-04T00:00:00.000Z","mah":"SCHERING","brand_name_local":null,"application_number":""},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1986-06-04T00:00:00.000Z","mah":"SCHERING","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1986-06-04T00:00:00.000Z","mah":"SCHERING","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1986-06-04T00:00:00.000Z","mah":"SCHERING","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1986-06-04T00:00:00.000Z","mah":"SCHERING","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1986-06-04T00:00:00.000Z","mah":"SCHERING","brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":null,"mah":null,"brand_name_local":"IntronA","application_number":"EMEA/H/C/000281"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"IntronA","application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:09:05.411610+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}